Abstract LB-287: Combination therapies with CDK4/6 inhibitors to treat <i>KRAS-</i>mutant pancreatic cancer
Craig M. Goodwin(University of North Carolina at Chapel Hill), Channing J. Der(University of North Carolina at Chapel Hill), Patrick J. Roberts(Argos Therapeutics (United States)), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Daniel M. Freed(Triangle), Andrew M. Waters(University of North Carolina at Chapel Hill), Sehrish Javaid(University of North Carolina at Chapel Hill), Kris C. Wood(Duke University), Mariaelena Pierobon(George Mason University), Autumn J. McRee(University of North Carolina at Chapel Hill), Adrienne D. Cox(University of North Carolina at Chapel Hill), Runying Yang(University of Alberta), Bjoern Papke(University of North Carolina at Chapel Hill)
Cited by 1
Related Papers
Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation
|Journal of Clinical Investigation|2014|717
Rho-family GTPases: it's not only Rac and Rho (and I like it)
|Journal of Cell Science|2004|594